Tirzepatide currently being a dual GLP-one and GIP agonist, it is instructed which the GIP element of dual agonism may be liable for the additional profit, given the possible advantage of GIP receptor agonism on peripheral insulin sensitization. Consequently, tirzepatide was simpler than dulaglutide in lowering fasting dietary TAG [6,7]. https://devinexncr.blogsmine.com/28553311/manual-article-review-is-required-for-this-article